Celldex Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Celldex Therapeutics, Inc. (CLDX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Celldex Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.41M, a 8.52% decline year-over-year.
- Celldex Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.52M, a 8.51% decline year-over-year.
- Celldex Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.80M, a 8.51% decline year-over-year.
- Celldex Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $9.19M, a 20.30% increase year-over-year.
- Celldex Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $36.22M, a 5.77% increase from fiscal 2024.
- Celldex Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $34.24M, a 43.33% increase from fiscal 2023.
- Celldex Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $23.89M, a 53.03% increase from fiscal 2022.
- Celldex Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $15.61M, a 74.37% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.41M 10-Q · filed 2026-08-06 | $16.93M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $8.52M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $36.22M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $8.80M 10-Q · filed 2025-11-10 | $17.99M derived: sum of 2 quarters · filed 2026-08-06 | $27.31M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $9.19M 10-Q · filed 2026-08-06 | $18.51M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $9.32M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $34.24M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $9.62M 10-Q · filed 2025-11-10 | $17.26M derived: sum of 2 quarters · filed 2025-11-10 | $24.46M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $7.64M 10-Q · filed 2025-11-10 | $14.84M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $7.20M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $23.89M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $7.12M 10-Q · filed 2024-11-06 | $12.34M derived: sum of 2 quarters · filed 2024-11-06 | $16.68M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $5.22M 10-Q · filed 2024-11-06 | $9.56M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $4.34M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $15.61M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $4.50M 10-Q · filed 2023-11-02 | $7.95M derived: sum of 2 quarters · filed 2023-11-02 | $11.10M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | $3.45M 10-Q · filed 2023-11-02 | $6.61M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $3.15M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $8.95M 10-K · filed 2024-02-26 | |||
| 2021-09-30 | $3.03M 10-Q · filed 2022-11-09 | $4.54M derived: sum of 2 quarters · filed 2022-11-09 | $5.81M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $1.51M 10-Q · filed 2022-11-09 | $2.78M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $1.27M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $3.92M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $1.25M 10-Q · filed 2021-11-09 | $1.97M derived: sum of 2 quarters · filed 2021-11-09 | $2.66M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $722.00K 10-Q · filed 2021-11-09 | $1.41M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $686.00K 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $4.55M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $707.00K 10-Q · filed 2020-11-05 | $2.17M derived: sum of 2 quarters · filed 2020-11-05 | $3.86M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $1.46M 10-Q · filed 2020-11-05 | $3.16M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $1.69M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $8.08M 10-K · filed 2021-03-29 | |||
| 2018-09-30 | $1.79M 10-Q · filed 2019-11-12 | $3.84M derived: sum of 2 quarters · filed 2019-11-12 | $6.33M derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $2.05M 10-Q · filed 2019-11-12 | $4.54M derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $2.49M 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $12.31M 10-K · filed 2020-03-26 | |||
| 2016-12-31 | $15.32M 10-K · filed 2019-03-07 | |||
| 2015-12-31 | $12.77M 10-K · filed 2018-03-07 | |||
| 2014-12-31 | $6.85M 10-K · filed 2017-03-14 | |||
| 2013-12-31 | $4.55M 10-K/A · filed 2016-02-25 | |||
| 2012-12-31 | $2.30M 10-K · filed 2015-02-24 | |||
| 2011-12-31 | $2.34M 10-K · filed 2014-03-03 | |||
| 2010-12-31 | $2.80M 10-K · filed 2013-03-08 | |||
| 2009-12-31 | $3.06M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |